一场旷日持久的mRNA疫苗专利纷争,最终以和解的方式落幕。日前,德国生物科技公司CureVac宣布与辉瑞和BioNTech达成协议,解决并终止关于mRNA相关疫苗的所有未决专利纠纷。根据协议条款,CureVac和葛兰素史克(GSK)将获得总计7.4亿美元的付款,以及该疫苗在美国未来销售收益的个位数百分比特许权使用费。此外,CureVac还将从GSK获得5000万美元的付款,用于货币化部分美国产品...
Source Link一场旷日持久的mRNA疫苗专利纷争,最终以和解的方式落幕。日前,德国生物科技公司CureVac宣布与辉瑞和BioNTech达成协议,解决并终止关于mRNA相关疫苗的所有未决专利纠纷。根据协议条款,CureVac和葛兰素史克(GSK)将获得总计7.4亿美元的付款,以及该疫苗在美国未来销售收益的个位数百分比特许权使用费。此外,CureVac还将从GSK获得5000万美元的付款,用于货币化部分美国产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.